Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Starpharma Holdings ADR News

    0,9419 $ +2,38% +0,0219 $
    In : 0,8785 € | 22.04.24 15:30:00 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2QE42
    ISIN: US8555631022
    US-Symbol: SPHRY
    Typ: Aktie

    Starpharma Holdings ADR News

    19.09.23 - PR Newswire
    Nasal Spray VIRALEZE™ For Respiratory and Cold Viruses, Including New Strains
    Nasal Spray VIRALEZE™ For Respiratory and Cold Viruses, Including New Strains PR Newswire
    12.09.22 - PR Newswire
    Starpharma presents compelling data in Prostate Cancer at ESMO
    Starpharma presents compelling data in Prostate Cancer at ESMO PR Newswire
    12.09.22 - PR Newswire
    Starpharma presents compelling data in Prostate Cancer at ESMO
    Starpharma presents compelling data in Prostate Cancer at ESMO PR Newswire
    10.08.22 - PR Newswire
    Starpharma signs new DEP® agreement with MSD
    Starpharma signs new DEP® agreement with MSD PR Newswire
    21.07.22 - PR Newswire
    VIRALEZE™ Nasenspray schützt vor hochinfektiösem Omikron im viralen Herausforderungsmodell - vor oder nach Virusexposition
    VIRALEZE™ Nasenspray schützt vor hochinfektiösem Omikron im viralen Herausforderungsmodell - vor oder nach Virusexposition PR Newswire
    20.07.22 - PR Newswire
    VIRALEZE™ Nasal Spray Protects Against Highly Infectious Omicron in Viral Challenge Model - Before or After Viral Exposure
    VIRALEZE™ Nasal Spray Protects Against Highly Infectious Omicron in Viral Challenge Model - Before or After Viral Exposure PR Newswire
    30.06.22 - PR Newswire
    Das in Australien entwickelte VIRALEZE™ Nasenspray wird von LloydsPharmacy in Großbritannien wieder eingeführt
    Das in Australien entwickelte VIRALEZE™ Nasenspray wird von LloydsPharmacy in Großbritannien wieder eingeführt PR Newswire
    30.06.22 - PR Newswire
    Australian developed VIRALEZE™ nasal spray relaunched by LloydsPharmacy in the UK
    Australian developed VIRALEZE™ nasal spray relaunched by LloydsPharmacy in the UK PR Newswire
    26.11.21 - PR Newswire
    Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel
    Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel PR Newswire
    26.11.21 - PR Newswire
    Starpharma releases positive DEP® phase 2 interim results in prostate cancer
    Starpharma releases positive DEP® phase 2 interim results in prostate cancer PR Newswire
    08.10.21 - PR Newswire
    VIRALEZE™ antivirales Nasenspray in den Apotheken der ADMENTA Italia Gruppe in Italien eingeführt
    VIRALEZE™ antivirales Nasenspray in den Apotheken der ADMENTA Italia Gruppe in Italien eingeführt PR Newswire
    08.10.21 - PR Newswire
    VIRALEZE™ antiviral nasal spray launched in ADMENTA Italia Group pharmacies in Italy
    VIRALEZE™ antiviral nasal spray launched in ADMENTA Italia Group pharmacies in Italy PR Newswire
    15.09.21 - PR Newswire
    US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments
    US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-​stage cancer treatments PR Newswire
    23.08.21 - PR Newswire
    Studie bestätigt, dass Viraleze antivirales Nasenspray Schutz gegen SARS-CoV-2 im Challenge-Modell bietet
    Studie bestätigt, dass Viraleze antivirales Nasenspray Schutz gegen SARS-CoV-2 im Challenge-​Modell bietet PR Newswire
    23.08.21 - PR Newswire
    Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model
    Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model PR Newswire
    23.08.21 - PR Newswire
    Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model
    Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model PR Newswire
    28.07.21 - PR Newswire
    Antivirale Wirkung von VIRALEZE SPL7013 ist >99,99% effektiv gegen Delta-Variante
    Antivirale Wirkung von VIRALEZE SPL7013 ist >99,99% effektiv gegen Delta-​Variante PR Newswire
    27.07.21 - PR Newswire
    VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant
    VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant PR Newswire
    11.02.21 - PR Newswire
    Starpharma signs DEP® ADC Research Agreement with MSD
    Starpharma signs DEP® ADC Research Agreement with MSD PR Newswire
    22.06.20 - PR Newswire
    Global Company Investor Presentations Now Available for On-Demand Viewing
    Global Company Investor Presentations Now Available for On-Demand Viewing Individual and institutional investors as well as advisors are invited to log-on to ...

    Newssuche

    Videos

    newspaper
    26.04.24 +10,71%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »